Clinical Trial Update: An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants [NA]

View source ↗

Summary

An 8-week open-label study evaluated acamprosate calcium as augmentation therapy for anxiety symptoms in patients with partial response to SSRI/SNRI antidepress…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorders

Drugs mentioned

• Campral (acamprosate)

Snippet

Sponsor: State University of New York - Upstate Medical University | Conditions: Anxiety | NA | Status: COMPLETED | Results posted: 2014-12-18